SEC Filing Summary
Entity and period: The supplied filing is Retrophin, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2014, not a filing under the name Travere Therapeutics, Inc. Verify the company identity before relying on this summary.
Business context and reporting period
Retrophin described itself as a biopharmaceutical company developing, acquiring, and commercializing therapies for serious and rare diseases. Following its Manchester Pharmaceuticals acquisition and Thiola license, it reported sales of Chenodal, Vecamyl, and Thiola. Its development programs included Sparsentan, RE-024, and RE-034. The filing covers the three and nine months ended September 30, 2014, compared with the corresponding 2013 periods.
Financial performance and position
| Metric | Q3 2014 | Nine months 2014 | Comparable 2013 |
|---|---|---|---|
| Net product sales | $8.35 million | $14.12 million | $0 |
| Operating expenses | $31.79 million | $75.02 million | $5.15 million / $12.50 million |
| Operating loss | $23.44 million | $60.90 million | $5.15 million / $12.50 million |
| Net loss | $19.56 million | $81.70 million | $10.90 million / $20.69 million |
| Cash used in operating activities | $36.76 million | $9.44 million |
Q3 cost of goods sold was $0.20 million, implying a high reported product gross margin before other expenses; the filing does not present a gross-margin percentage. Q3 net loss per basic share was $0.73; nine-month basic loss per share was $3.24.
At September 30, cash was $25.86 million and marketable securities were $11.93 million. Current assets were $45.44 million versus current liabilities of $49.13 million, a working-capital deficit of approximately $3.69 million. Total assets were $145.93 million, total liabilities $156.12 million, and stockholders’ deficit $10.19 million. Debt carrying values included $40.16 million under the secured credit facility and $43.13 million in convertible notes; stated principal maturities totaled $91 million.
Cash increased by $19.86 million during the nine months, primarily reflecting $95.85 million of financing cash inflows, including equity proceeds and new debt, partly offset by operating and investing cash outflows. The company reported $14.28 million of nine-month expense from changes in fair value of warrant liabilities; this non-cash valuation item materially affected reported results.
Material changes versus the prior comparable period
- Product sales began in 2014 after the Manchester acquisition and Thiola license; no product sales were reported for the 2013 comparison periods.
- Nine-month operating expenses rose to $75.02 million from $12.50 million, primarily due to higher R&D, personnel, professional fees, and commercialization activity.
- Nine-month net loss rose to $81.70 million from $20.69 million, while operating cash use increased to $36.76 million from $9.44 million.
- Manchester added substantial product-rights intangible assets and contingent royalty obligations. The company also obtained significant debt financing and issued equity.
Outlook, risks, contingencies, and unusual items
- Going concern: Management stated that continued operations depend on operating results and further financing; the filing says these conditions raise substantial doubt about the company’s ability to continue as a going concern. Management expected continued losses and gave no assurance that additional financing would be available on acceptable terms.
- Spending plans: The company estimated $6–$8 million for clinical trials through September 2015 and approximately $6–$8 million for preclinical work. It planned continued commercialization, pipeline development, and potential acquisitions; these are estimates, not assured funding or outcomes.
- Credit covenant breach: The company was out of compliance with certain secured-credit covenants at September 30. A November 13, 2014 amendment addressed certain covenant compliance and revised later tests, in exchange for warrants covering up to 300,000 shares.
- Proposed asset sale and leadership changes: An October 13 letter of intent proposed selling Vecamyl, Syntocinon, and ketamine assets to Turing Pharmaceuticals for $3 million upfront plus assumption of certain liabilities, subject to definitive documentation and consents. Turing’s CEO was former Retrophin CEO Martin Shkreli. The company recorded $2.9 million of severance expense related to the proposed sale and Shkreli’s separation; the transaction was not completed as of the filing.
- Other unusual items: The company recorded $4.7 million of finance expense related to shares issued to convertible-note holders and substantial stock-based compensation. It also held an approximately 7% stake in Clinuvel as of November 12 and had proposed an acquisition requiring additional financing if pursued.
- Legal matters: Disclosed matters included a Schwab suit alleging damages exceeding $2.5 million, the company’s antitrust suit against Questcor, a shareholder action seeking alleged $1.5 million short-swing profits, and a putative securities class action filed in October. Outcomes were uncertain.
- Controls: Management concluded disclosure controls were ineffective and identified material weaknesses involving timely financial data, complex accounting/reporting, and segregation of duties. Remediation was underway; the company expected operational effectiveness by year-end 2014.
Important facts for investors to verify
- Confirm that the filing belongs to the intended issuer: the document names Retrophin, Inc., while the request metadata names Travere Therapeutics, Inc.
- Review subsequent filings for cash runway, financing availability, operating cash burn, and progress toward positive cash flow.
- Check compliance with amended credit covenants, debt service costs, and any further lender amendments or warrant dilution.
- Verify whether the Turing asset sale closed, its final terms, and related-party safeguards given the former CEO’s role at the buyer.
- Track product revenue concentration: one customer represented 97% of revenue and 100% of accounts receivable at quarter-end.
- Monitor litigation, internal-control remediation, and the valuation and cash implications of contingent royalties and warrant liabilities.